Advertisement

---

ROYALTY PHARMA

Royalty Pharma Announces Withdrawal Of Judicial Review And Lapse Of Offer

[2013-06-18] -


Royalty Pharma Chairman Writes Open Letter to Elan Board

[2013-06-17] - Expresses Disappointment at Elan's Unwillingness to Negotiate Improved Terms in a Recommended Transaction Structured as a Scheme of Arrangement


Royalty Pharma Informs Elan Stockholders About The Consequences Arising From The Results Of The Elan EGM Earlier Today

[2013-06-17] -


Elan ADS Holders Decisively Vote Against Theravance And AOP Transactions

[2013-06-14] - VOTE OF ORDINARY SHAREHOLDERS MAY DETERMINE WHETHER ROYALTY PHARMA'S OFFER OF $13 IN CASH PLUS AN UP TO $2.50 CVR WILL BE PERMITTED TO PROCEED
VOTE "AGAINST" ALL FOUR TRANSACTIONS


Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty

[2013-06-14] - Ordinary Shareholders Urged to Vote AGAINST All Four Proposals Today to Allow Royalty Pharma's Offer of $13 per Share Plus an up to $2.50 CVR to Move Forward
Royalty Pharma Believes Sudden Sales Process Announced by Elan Friday, After Not Engaging with Royalty Pharma's Bid for Four Months, is a Clear Frustrating Tactic


Royalty Pharma Announces Offer May Lapse (Be Withdrawn)

[2013-06-13] -


Royalty Pharma Acceptances Announcement

[2013-06-11] -


Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit

[2013-06-11] - Elan's US Lawsuit Was Entirely Without Merit, Royalty Pharma Says Voluntary Withdrawal Confirms that Disclosures Have Been Full and Accurate, and Investors Have All Information Needed to Consider Royalty Pharma's Increased Tender Offer


In Royalty Pharma's View, Elan's EGM Circular is Misleading and Omits Key Information that Elan Shareholders Need to Make an Informed Decision

[2013-06-11] - IF ELAN STOCKHOLDERS APPROVE ANY OF THE FOUR PROPOSED TRANSACTIONS, ROYALTY PHARMA WILL BE REQUIRED TO LAPSE ITS OFFER(I),(II)
ROYALTY PHARMA RECOMMENDS ELAN SHAREHOLDERS VOTE "AGAINST" EACH OF THE ELAN RESOLUTIONS AT THE ELAN EXTRAORDINARY GENERAL MEETING


Royalty Pharma Files Judicial Review Proceedings

[2013-06-11] -


Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today

[2013-06-10] - ADS Shareholders Have Only Three Days to Vote
ISS and Glass Lewis Also Recommend Elan Shareholders Vote AGAINST ALL FOUR Resolutions*
Royalty Pharma Will Lapse its Offer if the Resolutions Are Approved [1],[2]


Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan

[2013-06-10] - Urges Shareholders to Vote AGAINST ALL PROPOSALS at Upcoming Elan EGM
Royalty Pharma Offers Compelling Immediate Value with Continued Upside participation
Voting Deadline for ADS Beneficial Holders in Street Name is this Wednesday at 11:59 p.m. ET


Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit

[2013-06-10] - Elan's US Lawsuit Was Entirely Without Merit, Royalty Pharma Says Voluntary Withdrawal Confirms that Disclosures Have Been Full and Accurate, and Investors Have All Information Needed to Consider Royalty Pharma's Increased Tender Offer


Royalty Pharma Acceptances Announcement

[2013-06-07] -


Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share

[2013-06-07] - CVR Allows Shareholders to Participate in Tysabri Royalty Upside for all Indications and Cash Flows, Pre- and Post-Patent Expiration
Offer Represents Premium of 56% to 97% to Elan's Undisturbed Enterprise Value
Royalty Pharma's Offer Will Lapse if Shareholders Approve Any Resolutions at Elan's Extraordinary General Meeting


Royalty Pharma Announces Extension of its Increased Offer

[2013-06-06] -


Royalty Pharma Statement Regarding Elan Law Suits

[2013-06-05] - Royalty Pharma Deplores What it Believes Are Efforts by Elan to Deprive Shareholders of an Opportunity to Consider Royalty Pharma Offer
Elan Withdraws Law Suit in Ireland After Court Confirms Jurisdiction of Irish Takeover Panel
Elan Law Suit in the United States is Entirely Without Merit, Royalty Pharma Says


Royalty Pharma Statement Regarding Elan Law Suits

[2013-06-05] - Royalty Pharma Deplores What it Believes Are Efforts by Elan to Deprive Shareholders of an Opportunity to Consider Royalty Pharma Offer
Elan Withdraws Law Suit in Ireland After Court Confirms Jurisdiction of Irish Takeover Panel
Elan Law Suit in the United States is Entirely Without Merit, Royalty Pharma Says


Royalty Pharma Responds To Elan's Tysabri Valuation

[2013-05-31] -


Royalty Pharma Response To Elan's "Categorical View On Value"

[2013-05-30] -


1 - 2
Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers